Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on June 30, 2021, a capital increase of 306,800 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor, and to other investors through its Open Market Sale AgreementSM with Jefferies LLC. As a result, the Company’s share capital is increased to 53,912,224.33 EUR and is represented by 15,493,956 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on 30 June 2021 following the Capital Increase:
|Total amount of share capital (EUR)||53,912,224.33|
|Total Number of shares with single voting rights||13,125,931|
|Total Number of shares with double voting rights||2,368,025|
|Total Number of Shares||15,493,956|
|Total of voting rights||17,861,981|
|Total number of attributed warrants||1,922,423|
|Total number of shares with voting rights that could be created following the exercise of the attributed warrants||1,922,423|
|Total number of diluted shares (Outstanding shares + Warrants)||17,416,379|
|Total number of diluted shares with voting rights||19,784,404|
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): email@example.com.
Further questions about the content of this release can be sent to firstname.lastname@example.org.